Biomarin Pharmaceutical Inc at Jefferies London Healthcare Conference Transcript
Good afternoon. This is Eun Yang, a biotech analyst with Jefferies based in New York. Our next presenting company is BioMarin. I'm sure that almost all of you know the -- know BioMarin quite well, and it doesn't really need any kind of introduction from my part.
This presentation is going to be a kind of a hybrid format where J.J. is going to provide us with an overview of the company, about 10 minutes. Then we are going to be doing Q&A. So presenting from BioMarin is J.J. Bienaimé, CEO and Chairman of the company. J.J.?
©,-&
Thank you. Good afternoon, everybody. Pleasure to be here. So I only have like 5 slides, and then we'll move to Q&A. And so just to -- big, big picture of where we come from, where we're going. So this company was definitely built over the last 21 years now on ultra-orphan disorders, mainly around lysosomal
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |